1
|
Mathieu-Rivet E, Mati-Baouche N, Walet-Balieu ML, Lerouge P, Bardor M. N- and O-Glycosylation Pathways in the Microalgae Polyphyletic Group. FRONTIERS IN PLANT SCIENCE 2020; 11:609993. [PMID: 33391324 PMCID: PMC7773692 DOI: 10.3389/fpls.2020.609993] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 11/23/2020] [Indexed: 05/15/2023]
Abstract
The term microalga refers to various unicellular and photosynthetic organisms representing a polyphyletic group. It gathers numerous species, which can be found in cyanobacteria (i.e., Arthrospira) as well as in distinct eukaryotic groups, such as Chlorophytes (i.e., Chlamydomonas or Chlorella) and Heterokonts (i.e., diatoms). This phylogenetic diversity results in an extraordinary variety of metabolic pathways, offering large possibilities for the production of natural compounds like pigments or lipids that can explain the ever-growing interest of industrials for these organisms since the middle of the last century. More recently, several species have received particular attention as biofactories for the production of recombinant proteins. Indeed, microalgae are easy to grow, safe and cheap making them attractive alternatives as heterologous expression systems. In this last scope of applications, the glycosylation capacity of these organisms must be considered as this post-translational modification of proteins impacts their structural and biological features. Although these mechanisms are well known in various Eukaryotes like mammals, plants or insects, only a few studies have been undertaken for the investigation of the protein glycosylation in microalgae. Recently, significant progresses have been made especially regarding protein N-glycosylation, while O-glycosylation remain poorly known. This review aims at summarizing the recent data in order to assess the state-of-the art knowledge in glycosylation processing in microalgae.
Collapse
Affiliation(s)
| | | | | | - Patrice Lerouge
- UNIROUEN, Laboratoire Glyco-MEV EA4358, Normandie Université, Rouen, France
| | - Muriel Bardor
- UNIROUEN, Laboratoire Glyco-MEV EA4358, Normandie Université, Rouen, France
- Unité de Glycobiologie Structurale et Fonctionnelle (UGSF), UMR 8576, CNRS, Université de Lille, Lille, France
- *Correspondence: Muriel Bardor,
| |
Collapse
|
2
|
Nguyen LN, Baumann M, Dhiman H, Marx N, Schmieder V, Hussein M, Eisenhut P, Hernandez I, Koehn J, Borth N. Novel Promoters Derived from Chinese Hamster Ovary Cells via In Silico and In Vitro Analysis. Biotechnol J 2019; 14:e1900125. [DOI: 10.1002/biot.201900125] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2019] [Revised: 05/14/2019] [Indexed: 12/13/2022]
Affiliation(s)
- Ly N. Nguyen
- Department of BiotechnologyBOKU University of Natural Resources and Life SciencesMuthgasse 18 1190 Vienna Austria
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| | - Martina Baumann
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| | - Heena Dhiman
- Department of BiotechnologyBOKU University of Natural Resources and Life SciencesMuthgasse 18 1190 Vienna Austria
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| | - Nicolas Marx
- Department of BiotechnologyBOKU University of Natural Resources and Life SciencesMuthgasse 18 1190 Vienna Austria
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| | - Valerie Schmieder
- Department of BiotechnologyBOKU University of Natural Resources and Life SciencesMuthgasse 18 1190 Vienna Austria
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| | - Mohamed Hussein
- Department of BiotechnologyBOKU University of Natural Resources and Life SciencesMuthgasse 18 1190 Vienna Austria
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| | - Peter Eisenhut
- Department of BiotechnologyBOKU University of Natural Resources and Life SciencesMuthgasse 18 1190 Vienna Austria
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| | | | | | - Nicole Borth
- Department of BiotechnologyBOKU University of Natural Resources and Life SciencesMuthgasse 18 1190 Vienna Austria
- Austrian Center of Industrial Biotechnology GmbH1190 Vienna Austria
| |
Collapse
|
3
|
Galleguillos SN, Ruckerbauer D, Gerstl MP, Borth N, Hanscho M, Zanghellini J. What can mathematical modelling say about CHO metabolism and protein glycosylation? Comput Struct Biotechnol J 2017; 15:212-221. [PMID: 28228925 PMCID: PMC5310201 DOI: 10.1016/j.csbj.2017.01.005] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2016] [Revised: 01/09/2017] [Accepted: 01/12/2017] [Indexed: 11/15/2022] Open
Abstract
Chinese hamster ovary cells have been in the spotlight for process optimization in recent years, due to being the major, long established cell factory for the production of recombinant proteins. A deep, quantitative understanding of CHO metabolism and mechanisms involved in protein glycosylation has proven to be attainable through the development of high throughput technologies. Here we review the most notable accomplishments in the field of modelling CHO metabolism and protein glycosylation.
Collapse
Affiliation(s)
- Sarah N Galleguillos
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - David Ruckerbauer
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - Matthias P Gerstl
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - Nicole Borth
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - Michael Hanscho
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology, Vienna, Austria
| | - Jürgen Zanghellini
- Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria; Austrian Centre of Industrial Biotechnology, Vienna, Austria
| |
Collapse
|
4
|
Xu N, Ou J, Gilani AK, Zhou L, Liu M. High-level expression of recombinant IgG1 by CHO K1 platform. Front Chem Sci Eng 2015. [DOI: 10.1007/s11705-015-1531-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Cell Surface and Membrane Engineering: Emerging Technologies and Applications. J Funct Biomater 2015; 6:454-85. [PMID: 26096148 PMCID: PMC4493524 DOI: 10.3390/jfb6020454] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Revised: 06/08/2015] [Accepted: 06/12/2015] [Indexed: 12/31/2022] Open
Abstract
Membranes constitute the interface between the basic unit of life—a single cell—and the outside environment and thus in many ways comprise the ultimate “functional biomaterial”. To perform the many and often conflicting functions required in this role, for example to partition intracellular contents from the outside environment while maintaining rapid intake of nutrients and efflux of waste products, biological membranes have evolved tremendous complexity and versatility. This article describes how membranes, mainly in the context of living cells, are increasingly being manipulated for practical purposes with drug discovery, biofuels, and biosensors providing specific, illustrative examples. Attention is also given to biology-inspired, but completely synthetic, membrane-based technologies that are being enabled by emerging methods such as bio-3D printers. The diverse set of applications covered in this article are intended to illustrate how these versatile technologies—as they rapidly mature—hold tremendous promise to benefit human health in numerous ways ranging from the development of new medicines to sensitive and cost-effective environmental monitoring for pathogens and pollutants to replacing hydrocarbon-based fossil fuels.
Collapse
|
6
|
Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation. J Biotechnol 2014; 188:88-96. [DOI: 10.1016/j.jbiotec.2014.08.026] [Citation(s) in RCA: 82] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Revised: 07/24/2014] [Accepted: 08/19/2014] [Indexed: 01/10/2023]
|
7
|
Next generation delivery system for proteins and genes of therapeutic purpose: why and how? BIOMED RESEARCH INTERNATIONAL 2014; 2014:327950. [PMID: 25126554 PMCID: PMC4122142 DOI: 10.1155/2014/327950] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Accepted: 04/09/2014] [Indexed: 12/30/2022]
Abstract
Proteins and genes of therapeutic interests in conjunction with different delivery systems are growing towards new heights. "Next generation delivery systems" may provide more efficient platform for delivery of proteins and genes. In the present review, snapshots about the benefits of proteins or gene therapy, general procedures for therapeutic protein or gene delivery system, and different next generation delivery system such as liposome, PEGylation, HESylation, and nanoparticle based delivery have been depicted with their detailed explanation.
Collapse
|
8
|
Goh JSY, Liu Y, Chan KF, Wan C, Teo G, Zhang P, Zhang Y, Song Z. Producing recombinant therapeutic glycoproteins with enhanced sialylation using CHO-gmt4 glycosylation mutant cells. Bioengineered 2014; 5:269–73. [PMID: 24911584 DOI: 10.4161/bioe.29490] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Recombinant glycoprotein drugs require proper glycosylation for optimal therapeutic efficacy. Glycoprotein therapeutics are rapidly removed from circulation and have reduced efficacy if they are poorly sialylated. Ricinus communis agglutinin-I (RCA-I) was found highly toxic to wild-type CHO-K1 cells and all the mutants that survived RCA-I treatment contained a dysfunctional N-acetylglucosaminyltransferase I (GnT I) gene. These mutants are named CHO-gmt4 cells. Interestingly, upon restoration of GnT I, the sialylation of a model glycoprotein, erythropoietin, produced in CHO-gmt4 cells was shown to be superior to that produced in wild-type CHO-K1 cells. This addendum summarizes the applicability of this cell line, from transient to stable expression of the recombinant protein, and from a lab scale to an industrial scale perfusion bioreactor. In addition, CHO-gmt4 cells can be used to produce glycoproteins with mannose-terminated N-glycans. Recombinant glucocerebrosidase produced by CHO-gmt4 cells will not require glycan remodeling and may be directly used to treat patients with Gaucher disease. CHO-gmt4 cells can also be used to produce other glycoprotein therapeutics which target cells expressing mannose receptors.
Collapse
Affiliation(s)
- John S Y Goh
- Bioprocessing Technology Institute; Agency for Science, Technology, and Research (A*STAR); Singapore, Singapore
| | - Yingwei Liu
- State Key Laboratory of Bioreactor Engineering; East China University of Science and Technology; Shanghai, China
| | - Kah Fai Chan
- Bioprocessing Technology Institute; Agency for Science, Technology, and Research (A*STAR); Singapore, Singapore
| | - Corrine Wan
- Bioprocessing Technology Institute; Agency for Science, Technology, and Research (A*STAR); Singapore, Singapore
| | - Gavin Teo
- Bioprocessing Technology Institute; Agency for Science, Technology, and Research (A*STAR); Singapore, Singapore
| | - Peiqing Zhang
- Bioprocessing Technology Institute; Agency for Science, Technology, and Research (A*STAR); Singapore, Singapore
| | - Yuanxing Zhang
- State Key Laboratory of Bioreactor Engineering; East China University of Science and Technology; Shanghai, China
| | - Zhiwei Song
- Bioprocessing Technology Institute; Agency for Science, Technology, and Research (A*STAR); Singapore, Singapore
| |
Collapse
|
9
|
Stanley P, Sundaram S. Rapid assays for lectin toxicity and binding changes that reflect altered glycosylation in mammalian cells. ACTA ACUST UNITED AC 2014; 6:117-133. [PMID: 24903886 DOI: 10.1002/9780470559277.ch130206] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Glycosylation engineering is used to generate glycoproteins, glycolipids, or proteoglycans with a more defined complement of glycans on their glycoconjugates. For example, a mammalian cell glycosylation mutant lacking a specific glycosyltransferase generates glycoproteins, and/or glycolipids, and/or proteoglycans with truncated glycans missing the sugar transferred by that glycosyltransferase, as well as those sugars that would be added subsequently. In some cases, an alternative glycosyltransferase may then use the truncated glycans as acceptors, thereby generating a new or different glycan subset in the mutant cell. Another type of glycosylation mutant arises from gain-of-function mutations that, for example, activate a silent glycosyltransferase gene. In this case, glycoconjugates will have glycans with additional sugar(s) that are more elaborate than the glycans of wild type cells. Mutations in other genes that affect glycosylation, such as nucleotide sugar synthases or transporters, will alter the glycan complement in more general ways that usually affect several types of glycoconjugates. There are now many strategies for generating a precise mutation in a glycosylation gene in a mammalian cell. Large-volume cultures of mammalian cells may also generate spontaneous mutants in glycosylation pathways. This article will focus on how to rapidly characterize mammalian cells with an altered glycosylation activity. The key reagents for the protocols described are plant lectins that bind mammalian glycans with varying avidities, depending on the specific structure of those glycans. Cells with altered glycosylation generally become resistant or hypersensitive to lectin toxicity, and have reduced or increased lectin or antibody binding. Here we describe rapid assays to compare the cytotoxicity of lectins in a lectin resistance test, and the binding of lectins or antibodies by flow cytometry in a glycan-binding assay. Based on these tests, glycosylation changes expressed by a cell can be revealed, and glycosylation mutants classified into phenotypic groups that may reflect a loss-of-function or gain-of-function mutation in a specific gene involved in glycan synthesis.
Collapse
Affiliation(s)
- Pamela Stanley
- Department of Cell Biology, Albert Einstein College of Medicine, New York, New York
| | - Subha Sundaram
- Department of Cell Biology, Albert Einstein College of Medicine, New York, New York
| |
Collapse
|
10
|
Grainger RK, James DC. CHO cell line specific prediction and control of recombinant monoclonal antibodyN-glycosylation. Biotechnol Bioeng 2013; 110:2970-83. [DOI: 10.1002/bit.24959] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2013] [Revised: 04/30/2013] [Accepted: 05/06/2013] [Indexed: 12/20/2022]
Affiliation(s)
- Rhian K. Grainger
- ChELSI Institute, Department of Chemical and Biological Engineering; University of Sheffield; Mappin Street Sheffield S1 3JD UK
| | - David C. James
- ChELSI Institute, Department of Chemical and Biological Engineering; University of Sheffield; Mappin Street Sheffield S1 3JD UK
| |
Collapse
|